Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207335 | 0.85 | PIK3CG (0.37) | AHRLMNACYP1A2MAPTTHRB | |
| SCHEMBL207600 | 0.75 | AHR (0.37) | AHR | |
| SCHEMBL325358 | 0.71 | ALDH1A1 (0.41) | LMNACYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL2724 | 0.69 | — | — | |
| SCHEMBL8611907 | 0.67 | KDM4E (0.35) | CYP1A2MAPTALDH1A1PSMB8KMT2A | |
| SCHEMBL4306677 | 0.65 | — | — | |
| SCHEMBL208915 | 0.64 | AHR (0.38) | AHRLMNACYP1A2MAPTTHRB | |
| SCHEMBL8613814 | 0.63 | KDM4E (0.40) | LMNACYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL7976274 | 0.61 | LMNA (0.40) | AHRLMNACYP1A2MAPTTHRB | |
| SCHEMBL11030089 | 0.61 | TP53 (0.43) | AHRLMNAALOX15MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | claimed |
| EP-3946345-A1 | METHODS OF TREATING NEUROPATHIC PAIN | Intra-Cellular Therapies, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3914235-A2 | METHODS OF TREATING ADDICTION | Intra-Cellular Therapies, Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| WO-2020206391-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-10-08 | — | — | WO | claimed |
| WO-2020154519-A2 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2020132605-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-25 | — | — | WO | claimed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | claimed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | claimed |
| WO-2023069880-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3946345-A1 | METHODS OF TREATING NEUROPATHIC PAIN | Intra-Cellular Therapies, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3914235-A2 | METHODS OF TREATING ADDICTION | Intra-Cellular Therapies, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-0789692-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997000859-A1 | THIOAMIDES S-OXIDES FOR USE AS PESTICIDES | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | disclosed |
| WO-1996014305-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-05-17 | — | — | WO | disclosed |
| EP-0277794-B1 | N-heterocyclic-N-(4-piperidyl) amides | OHMEDA PHARMA PROD (US) | 1994-04-20 | — | — | EP | disclosed |
| US-4900738-A | OPIOID ANTAGONISTS; REDUCE SIDE EFFECTS | BOC, INC. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4791112-A | ANALGESICS, NAQRCOTIC ANTAGONISTS | THE BOC GROUP, INC. (US) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184072-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | AHR 4251/4885LMNA 2354/4885CYP1A2 2735/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | AHR 606/4885LMNA 3945/4885CYP1A2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.